{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:22:16Z","timestamp":1779200536748,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-022-03420-0","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T16:03:27Z","timestamp":1669651407000},"page":"1255-1262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial"],"prefix":"10.1007","volume":"55","clinical-trial-number":[{"clinical-trial-number":"tctr20210316009","registry":"10.18810\/tctr"}],"author":[{"given":"Wutipong","family":"Triwatana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-0942","authenticated-orcid":false,"given":"Bancha","family":"Satirapoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ouppatham","family":"Supasyndh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naowanit","family":"Nata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"issue":"11","key":"3420_CR1","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121(11):4393\u20134408. https:\/\/doi.org\/10.1172\/JCI46122","journal-title":"J Clin Invest"},{"issue":"23","key":"3420_CR2","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M (2011) Chronic renal insufficiency cohort study G fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305(23):2432\u20132439. https:\/\/doi.org\/10.1001\/jama.2011.826","journal-title":"JAMA"},{"issue":"7","key":"3420_CR3","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/CJN.13281211","volume":"7","author":"J Munoz Mendoza","year":"2012","unstructured":"Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M, Chronic Renal Insufficiency C (2012) Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 7(7):1155\u20131162. https:\/\/doi.org\/10.2215\/CJN.13281211","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2\u20133","key":"3420_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.32725\/jab.2020.005","volume":"18","author":"M Marchelek-Mysliwiec","year":"2020","unstructured":"Marchelek-Mysliwiec M, Dziedziejko V, Dolegowka K, Pawlik A, Safranow K, Stepniewska J, Wisniewska M, Malyszko J, Ciechanowski K (2020) Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease. J Appl Biomed 18(2\u20133):61\u201369. https:\/\/doi.org\/10.32725\/jab.2020.005","journal-title":"J Appl Biomed"},{"issue":"1","key":"3420_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jdiacomp.2013.09.004","volume":"28","author":"JS Garland","year":"2014","unstructured":"Garland JS, Holden RM, Ross R, Adams MA, Nolan RL, Hopman WM, Morton AR (2014) Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3\u20135 chronic kidney disease patients. J Diabetes Complicat 28(1):61\u201365. https:\/\/doi.org\/10.1016\/j.jdiacomp.2013.09.004","journal-title":"J Diabetes Complicat"},{"issue":"1","key":"3420_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/0886022X.2018.1455594","volume":"40","author":"A Fayed","year":"2018","unstructured":"Fayed A, El Nokeety MM, Heikal AA, Abdulazim DO, Naguib MM, Sharaf El Din UAA, Vascular Calcification G (2018) Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients. Ren Fail 40(1):226\u2013230. https:\/\/doi.org\/10.1080\/0886022X.2018.1455594","journal-title":"Ren Fail"},{"issue":"22","key":"3420_CR7","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.1800160115","volume":"115","author":"L Bar","year":"2018","unstructured":"Bar L, Feger M, Fajol A, Klotz LO, Zeng S, Lang F, Hocher B, Foller M (2018) Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc Natl Acad Sci U S A 115(22):5804\u20135809. https:\/\/doi.org\/10.1073\/pnas.1800160115","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"3420_CR8","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.2165\/00003495-200363130-00004","volume":"63","author":"M Diamant","year":"2003","unstructured":"Diamant M, Heine RJ (2003) Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 63(13):1373\u20131405","journal-title":"Drugs"},{"issue":"2","key":"3420_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2174\/1874467211205020272","volume":"5","author":"G Derosa","year":"2012","unstructured":"Derosa G, Maffioli P (2012) Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 5(2):272\u2013281. https:\/\/doi.org\/10.2174\/1874467211205020272","journal-title":"Curr Mol Pharmacol"},{"issue":"6","key":"3420_CR10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2215\/CJN.09250912","volume":"8","author":"T Isakova","year":"2013","unstructured":"Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, Xie H, Wahl P, Schiavenato E, Dosch A, Gutierrez OM, Diego J, Lenz O, Contreras G, Mendez A, Weiner RB, Wolf M (2013) Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 8(6):1009\u20131018. https:\/\/doi.org\/10.2215\/CJN.09250912","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"3420_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412\u2013419. https:\/\/doi.org\/10.1007\/BF00280883","journal-title":"Diabetologia"},{"issue":"5","key":"3420_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","volume":"90","author":"S Singh","year":"2016","unstructured":"Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, Di Marco GS, Brand M, Wolf M, Faul C (2016) Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 90(5):985\u2013996. https:\/\/doi.org\/10.1016\/j.kint.2016.05.019","journal-title":"Kidney Int"},{"issue":"2","key":"3420_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3810\/hp.2013.04.1062","volume":"41","author":"RA Defronzo","year":"1995","unstructured":"Defronzo RA, Mehta RJ (1995) Schnure JJ (2013) Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract 41(2):132\u2013147. https:\/\/doi.org\/10.3810\/hp.2013.04.1062","journal-title":"Hosp Pract"},{"issue":"8","key":"3420_CR14","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.2310\/JIM.0000000000000017","volume":"61","author":"YB Esterson","year":"2013","unstructured":"Esterson YB, Zhang K, Koppaka S, Kehlenbrink S, Kishore P, Raghavan P, Maginley SR, Carey M, Hawkins M (2013) Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients. J Investig Med 61(8):1152\u20131160. https:\/\/doi.org\/10.2310\/JIM.0000000000000017","journal-title":"J Investig Med"},{"issue":"4","key":"3420_CR15","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1210\/jc.2016-3563","volume":"102","author":"S Zaheer","year":"2017","unstructured":"Zaheer S, de Boer IH, Allison M, Brown JM, Psaty BM, Robinson-Cohen C, Michos ED, Ix JH, Kestenbaum B, Siscovick D, Vaidya A (2017) Fibroblast growth factor 23, mineral metabolism, and adiposity in normal kidney function. J Clin Endocrinol Metab 102(4):1387\u20131395. https:\/\/doi.org\/10.1210\/jc.2016-3563","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3420_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/ATVBAHA.110.214619","volume":"31","author":"MA Mirza","year":"2011","unstructured":"Mirza MA, Alsio J, Hammarstedt A, Erben RG, Michaelsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellstrom D, Lind L, Ohlsson C, Larsson TE (2011) Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 31(1):219\u2013227. https:\/\/doi.org\/10.1161\/ATVBAHA.110.214619","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"3420_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.2337\/dc11-2235","volume":"35","author":"P Wahl","year":"2012","unstructured":"Wahl P, Xie H, Scialla J, Anderson CA, Bellovich K, Brecklin C, Chen J, Feldman H, Gutierrez OM, Lash J, Leonard MB, Negrea L, Rosas SE, Anderson AH, Townsend RR, Wolf M, Isakova T (2012) Chronic Renal Insufficiency Cohort Study G Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. Diabetes Care 35(5):994\u20131001. https:\/\/doi.org\/10.2337\/dc11-2235","journal-title":"Diabetes Care"},{"issue":"3","key":"3420_CR18","doi-asserted-by":"publisher","first-page":"e58007","DOI":"10.1371\/journal.pone.0058007","volume":"8","author":"JE Lee","year":"2013","unstructured":"Lee JE, Gohda T, Walker WH, Skupien J, Smiles AM, Holak RR, Jeong J, McDonnell KP, Krolewski AS, Niewczas MA (2013) Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1. PLoS ONE 8(3):e58007. https:\/\/doi.org\/10.1371\/journal.pone.0058007","journal-title":"PLoS ONE"},{"issue":"4","key":"3420_CR19","doi-asserted-by":"publisher","first-page":"E575","DOI":"10.1210\/jc.2011-2836","volume":"97","author":"M Schoppet","year":"2012","unstructured":"Schoppet M, Hofbauer LC, Brinskelle-Schmal N, Varennes A, Goudable J, Richard M, Hawa G, Chapurlat R, Szulc P (2012) Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab 97(4):E575-583. https:\/\/doi.org\/10.1210\/jc.2011-2836","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"3420_CR20","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.3390\/jcm10122583","volume":"10","author":"J Donate-Correa","year":"2021","unstructured":"Donate-Correa J, Martin-Nunez E, Gonzalez-Luis A, Ferri CM, Luis-Rodriguez D, Tagua VG, Mora-Fernandez C, Navarro-Gonzalez JF (2021) Pathophysiological implications of imbalances in fibroblast growth factor 23 in the development of diabetes. J Clin Med 10(12):2583. https:\/\/doi.org\/10.3390\/jcm10122583","journal-title":"J Clin Med"},{"issue":"7\u20138","key":"3420_CR21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1515\/jpem-2012-0064","volume":"25","author":"M Wojcik","year":"2012","unstructured":"Wojcik M, Janus D, Dolezal-Oltarzewska K, Drozdz D, Sztefko K, Starzyk JB (2012) The association of FGF23 levels in obese adolescents with insulin sensitivity. J Pediatr Endocrinol Metab 25(7\u20138):687\u2013690. https:\/\/doi.org\/10.1515\/jpem-2012-0064","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"3420_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2265.2011.04299.x","volume":"77","author":"M Wojcik","year":"2012","unstructured":"Wojcik M, Dolezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, Starzyk JB (2012) FGF23 contributes to insulin sensitivity in obese adolescents\u2014preliminary results. Clin Endocrinol (Oxf) 77(4):537\u2013540. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04299.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"3420_CR23","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.4161\/cc.10.10.15672","volume":"10","author":"A Rodriguez","year":"2011","unstructured":"Rodriguez A, Catalan V, Gomez-Ambrosi J, Fruhbeck G (2011) Aquaglyceroporins serve as metabolic gateways in adiposity and insulin resistance control. Cell Cycle 10(10):1548\u20131556. https:\/\/doi.org\/10.4161\/cc.10.10.15672","journal-title":"Cell Cycle"},{"issue":"2","key":"3420_CR24","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.dsx.2019.02.023","volume":"13","author":"MM Adeva-Andany","year":"2019","unstructured":"Adeva-Andany MM, Martinez-Rodriguez J, Gonzalez-Lucan M, Fernandez-Fernandez C, Castro-Quintela E (2019) Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metab Syndr 13(2):1449\u20131455. https:\/\/doi.org\/10.1016\/j.dsx.2019.02.023","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"3420_CR25","doi-asserted-by":"publisher","first-page":"e013927","DOI":"10.1136\/bmjopen-2016-013927","volume":"7","author":"HW Liao","year":"2017","unstructured":"Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B (2017) Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 7(1):e013927. https:\/\/doi.org\/10.1136\/bmjopen-2016-013927","journal-title":"BMJ Open"},{"issue":"6","key":"3420_CR26","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/dom.14687","volume":"24","author":"JD Spence","year":"2022","unstructured":"Spence JD, Viscoli C, Kernan WN, Young LH, Furie K, DeFronzo R, Abdul-Ghani M, Dandona P, Inzucchi SE (2022) Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. Diabetes Obes Metab 24(6):1150\u20131158. https:\/\/doi.org\/10.1111\/dom.14687","journal-title":"Diabetes Obes Metab"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03420-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03420-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03420-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T13:10:34Z","timestamp":1681564234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03420-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["3420"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03420-0","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"9 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Institute Review Board at the Royal Thai Army Medical Department and was conducted according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}